Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cole Mendenhall

Vascular & Interventional Radiology Phoenix, AZ Medical Doctor

NPI 1891958351 CMS profile 1311089

500 W Thomas Rd Ste 100, Phoenix, AZ 85013

Open in the dashboard

General payments

$6,089

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cole Mendenhall of Phoenix, AZ is reported in the CMS Open Payments database as having received $6,089 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,179 24
2024 General $939 31
2023 General $1,381 30
2022 General $640 21
2021 General $1,540 10
2020 General $36 2
2019 General $374 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cole Mendenhall
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Cole Mendenhall were reported at $1,179. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Cole Mendenhall Vascular & Interventional Radiology median Middle half National median
2019 $374 $422 $125–$1,555 $163
2020 $36 $200 $68–$652 $114
2021 $1,540 $280 $99–$866 $132
2022 $640 $433 $137–$1,497 $149
2023 $1,381 $506 $152–$2,019 $160
2024 $939 $556 $175–$1,930 $164
2025 $1,179 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $2,020 28 payments
  2. Boston Scientific Corporation $868 25 payments
  3. Sirtex Medical Inc $671 8 payments
  4. Medtronic, Inc. $605 17 payments
  5. AngioDynamics, Inc. $493 7 payments
  6. EKOS Corporation $261 8 payments
  7. Penumbra, Inc. $191 3 payments
  8. Abiomed $138 5 payments
  9. Imperative Care, INc $134 5 payments
  10. Surefire Medical, Inc. $130 3 payments
  11. Other $579 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,891 132 payments
  2. Travel and Lodging $1,198 2 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $2,087 31 payments
  2. CT THROMBECTOMY SYSTEM KIT $2,019 27 payments
  3. SIR-Spheres Microspheres $671 8 payments
  4. BioFlo $395 5 payments
  5. EKOSONIC $261 8 payments
  6. Pipeline $232 2 payments
  7. General - Embolics $172 1 payment
  8. CONCERTOTM $142 6 payments
  9. Impella $138 5 payments
  10. TheraSphere Y90 Glass Microspheres 10 GBq $137 1 payment
  11. Other $1,857 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

47

Median for Diagnostic Radiology: 24

Drug cost

$234

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin Hcl Generic 18 $146
Ibuprofen Generic 15 $60
Pantoprazole Sodium Generic 14 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$333,175

Of which drugs: $429

Medicare patients

232

Average age 72

Services billed

5,192

101 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 52%
Arthritis 49%
Ischemic heart disease 44%
Diabetes 41%
Heart failure 37%
Atrial fibrillation 37%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 27 4,121 $429

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record